HilleVax Investor Relations Material
Latest events
Q1 2025
8 May, 2025
Q4 2024
28 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HilleVax Inc
Access all reports
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company’s primary product under development is HIL-214, a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax has been working on advancing this vaccine through clinical trials, with efforts to evaluate its safety and efficacy across different age groups. Hillevax is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
HLVX
Country
🇺🇸 United States